Dawson Lim
Monongahela, PANPI 1356304513
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.5% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 8.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,395 and has fallen 98.0% since, to $48 in 2022.
Across 229 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$338
- Amgen$291
- AstraZeneca$260
- Seagen Inc.$245
- Pfizer$245
- Novartis$222
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,46191%
- Education$3229%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 31 | $338 |
| Amgen | 17 | $291 |
| AstraZeneca(2 entities) | 15 | $260 |
| Seagen Inc. | 12 | $245 |
| Pfizer | 17 | $245 |
| Novartis | 13 | $222 |
| Astellas Pharma US Inc | 7 | $219 |
| Merck | 11 | $196 |
| Lilly USA, LLC | 9 | $165 |
| Genentech USA, Inc. | 11 | $164 |
| Johnson & Johnson(2 entities) | 9 | $131 |
| Sanofi | 7 | $124 |
| Eisai Inc. | 6 | $106 |
| Bristol Myers Squibb | 6 | $104 |
| Incyte Corporation | 6 | $96 |
| Boehringer Ingelheim | 4 | $74 |
| Bayer | 4 | $68 |
| Gilead | 5 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Clovis Oncology, Inc. | 3 | $55 |
| GSK | 2 | $47 |
| Puma Biotechnology, Inc. | 3 | $46 |
| Rigel Pharmaceuticals, Inc. | 3 | $46 |
| Daiichi Sankyo Inc. | 2 | $44 |
| AbbVie | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Exelixis Inc. | 2 | $36 |
| Verastem, Inc. | 2 | $33 |
| Array Biopharma Inc | 2 | $31 |
| Taiho Oncology, Inc. | 2 | $31 |
| Tesaro, Inc. | 2 | $31 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $19 |
| Mylan Institutional Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Dova Pharmaceuticals | 1 | $13 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.